Clinical-stage biotech developing obicetrapib, an oral CETP inhibitor to lower LDL cholesterol for cardiovascular disease.
Clinical-stage biotech developing obicetrapib, an oral CETP inhibitor to lower LDL cholesterol for cardiovascular disease.
Has no approved product yet, so it relies on money raised from investors and on a licensing deal with Menarini, which holds the right to sell obicetrapib in Europe once approved and owes milestone and royalty payments back. Late-stage trials, including one on heart-attack and stroke outcomes, are what the value rests on.
Moat: none (IP / patents). Pre-commercial; must differentiate after past CETP-inhibitor failures at other companies.
Headquarters: Naarden, Netherlands · Founded: 2019 · Employees: 100
Size NewAmsterdam Pharma (NAMS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.37B, the 1676th largest of 3,085 United States companies the cockpit tracks. Shares closed at $19.74 on 18 Nov 2026.
Performance Over six months the shares fell 44.8%, against -9.7% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 26.4% over the last twelve months (peer median +4.2%); the operating margin is -900.1% (peer median 11.1%).
Valuation It trades at 67.0× enterprise value to sales against a peer median of 4.2× (most expensive of 20).
Short interest Short interest is 10.0% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $25.9M | $22.5M | $45.6M | $14.1M | $103M |
| Revenue growth | — | -51% | +223% | -86% | — |
| Gross profit | $25.7M | $22.3M | $45.5M | $14.0M | $103M |
| EBITDA | -$233M | -$225M | -$176M | -$181M | -$1.31M |
| Net income | -$205M | -$204M | -$242M | -$177M | -$22.6M |
| Free cash flow | -$151M | -$148M | -$159M | -$141M | $10.4M |
| Capital expenditure | $395,000 | $246,000 | $672,000 | $24,000 | $221,000 |
| Total debt | $76,000 | $202,000 | $448,000 | $60,000 | $126,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| NewAmsterdam Pharma NAMS | $2.37B | -45% | -26% | -900% | 67.0× | n/a |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 30% | 5.4× | -1.1% |
| Merck & MRK | $340B | +23% | +5% | 18% | 5.7× | 8.3% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 5.0× | 14.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NAMS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.2% | -4.4% | 8th lowest of 21 |
| 6-month return | -44.8% | -9.7% | 3rd lowest of 21 |
| Distance from 52-week high | -53.2% | -28.5% | 4th lowest of 21 |
| Revenue growth (TTM) | -26.4% | +4.2% | 3rd lowest of 20 |
| Operating margin | -900.1% | 11.1% | 2nd lowest of 19 |
| EV / Sales | 67.0× | 4.2× | most expensive of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | 67.0× | n/a | n/a |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | 11.8× | n/a | n/a |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 2.0× | 47.0% | +19.3% |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 1.3× | 14.1% | +0.8% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 16.8× | n/a | n/a |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 13.6× | 37.9% | +22.9% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 3.8× | 2.3% | +2.9% |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 14.0× | 41.3% | +27.7% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 1.9× | 6.1% | +6.5% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | 1.5× | -2.5% | -5.8% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 4.2× | 3.4% | +4.8% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 2.6× | 26.7% | +6.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 4.2× | 0.9% | +0.3% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 1.7× | -9.7% | -1.5% |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | 48.0× | n/a | n/a |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | 3.3× | n/a | n/a |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 25.1× | 25.5% | +100.1% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 4.0× | -11.0% | +37.6% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 12.9× | 37.4% | +6.1% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 8.4× | 3.2% | +15.7% |